BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
+0.05 (2.17%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.30 - 2.40
52 week 1.50 - 3.60
Open 2.35
Vol / Avg. 0.00/581,010.00
Mkt cap 131.33M
P/E 25.09
Div/yield     -
EPS 0.09
Shares 55.88M
Beta 0.82
Inst. own 45%
Dec 7, 2017
BioDelivery Sciences International Inc Annual Shareholders Meeting - 11:00AM EST - Add to calendar
Nov 28, 2017
BioDelivery Sciences International Inc at Piper Jaffray Healthcare Conference - 3:00PM EST - Add to calendar
Nov 9, 2017
Q3 2017 BioDelivery Sciences International Inc Earnings Call - Webcast
Nov 9, 2017
Q3 2017 BioDelivery Sciences International Inc Earnings Release
Oct 9, 2017
Dar Es Salaam Investment Bank PJSC Annual Shareholders Meeting (Estimated)
Sep 26, 2017
BioDelivery Sciences International Inc at Ladenburg Thalmann Healthcare Conference
Sep 25, 2017
BioDelivery Sciences International Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 12, 2017
BioDelivery Sciences International Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -106.20% -431.87%
Operating margin -89.27% -411.26%
EBITD margin - -402.21%
Return on average assets -51.66% -86.58%
Return on average equity -212.47% -957.27%
Employees 99 -
CDP Score - -


4131 Parklake Ave Ste 225
RALEIGH, NC 27612-2390
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr., M.D. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo Vice Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 63
Bio & Compensation  - Reuters
Niraj Vasisht Ph.D. Senior Vice President of Product Development and Chief Technical Officer
Age: 52
Bio & Compensation  - Reuters
Peter L. Ginsberg Vice President - Business Development
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Timothy C. Tyson Director
Age: 62
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 55
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 72
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters